Table 3 Distribution of AEFIs across antigens/vaccines
Variable | Total number of AEFIs (N = 387) n (%)a | Vaccine | P value | |||||
|---|---|---|---|---|---|---|---|---|
BCG (N = 20) n (%)a | Measles (N = 136) n (%)a | Measles inappropriate(N = 60) n (%)a | OPV/DTP booster (N = 10) n (%)a | OPV/DTP-Hib-HepB (N = 152) n (%)a | Unclassified (N = 9) n (%)a | |||
Type of AEFI | ||||||||
Systemic | 301(77.8) | 13(65.0) | 130(95.6) | 60 (100.0) | 6 (60.0) | 90(59.2) | 2(22.2) | < 0.0001 |
Local | 86(22.2) | 7(35.0) | 6(4.4) | 0(0.0) | 4(40.0) | 62(40.8) | 7(77.8) | |
Systemic AEFIs | ||||||||
Cough | 5(1.3) | 0 | 3 | 1 | 0 | 1 | 0 | 0.146 |
Diarrhoea | 23(5.9) | 0 | 3 | 5 | 0 | 15 | 0 | < 0.0001 |
Dyspnoea | 4(1.0) | 0 | 1 | 0 | 0 | 3 | 0 | 0.051 |
Hypersensitivity | 4(1.0) | 0 | 4 | 0 | 0 | 0 | 0 | 0.001 |
Occular Disorders | 17(4.4) | 0 | 14 | 3 | 0 | 0 | 0 | < 0.0001 |
Paralysis | 4(1.0) | 0 | 1 | 1 | 1 | 1 | 0 | 0.841 |
Pyrexia | 61(15.8) | 4 | 13 | 13 | 3 | 27 | 1 | < 0.0001 |
Seizure | 12(3.1) | 0 | 2 | 4 | 0 | 6 | 0 | 0.007 |
Vomiting | 25(6.5) | 0 | 4 | 8 | 0 | 12 | 1 | < 0.0001 |
Pruritus | 11(2.8) | 0 | 9 | 2 | 0 | 0 | 0 | < 0.0001 |
Rash | 49(12.7) | 1 | 33 | 11 | 1 | 3 | 0 | < 0.0001 |
Urticaria | 23(5.9) | 1 | 19 | 3 | 0 | 0 | 0 | < 0.0001 |
Other | 63(16.3) | 7 | 24 | 9 | 1 | 22 | 0 | |
Local AEFIs | ||||||||
Injection site Abscess | 75 (19.4) | 7 | 3 | 0 | 3 | 57 | 5 | < 0.0001 |
Injection site Swelling | 5(1.3) | 0 | 0 | 0 | 1 | 3 | 1 | 0.146 |
Other | 6(1.6) | 0 | 3 | 0 | 0 | 2 | 1 | 0.156 |